Nanotheragnostic applications for ischemic and hemorrhagic strokes: improved delivery for a better prognosis.
Stroke is the second leading cause of death worldwide and a major cause of long-term severe disability representing a global health burden and one of the highly researched medical conditions. Nanostructured material synthesis and engineering have been recently developed and have been largely integrated into many fields including medicine. Recent studies have shown that nanoparticles might be a valuable tool in stroke. Different types, shapes, and sizes of nanoparticles have been used for molecular/biomarker profiling and imaging to help in early diagnosis and prevention of stroke and for drug/RNA delivery for improved treatment and neuroprotection. However, these promising applications have limitations, including cytotoxicity, which hindered their adoption into clinical use. Future research is warranted to fully develop and effectively and safely translate nanoparticles for stroke diagnosis and treatment into the clinic. This work will discuss the emerging role of nanotheragnostics in stroke diagnosis and treatment applications.
Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon, tarek.mouhieddine@gmail.com.
Tarek H
TH
Mouhieddine
Muhieddine M
MM
Itani
Amaly
A
Nokkari
Changhong
C
Ren
Georges
G
Daoud
Asad
A
Zeidan
Stefania
S
Mondello
Firas H
FH
Kobeissy
D000818:Animals; D002545:Brain Ischemia / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D016503:Drug Delivery Systems; D006801:Humans; D020300:Intracranial Hemorrhages / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D053758:Nanoparticles / Q000009:adverse effects / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000008:administration & dosage; D011379:Prognosis; D020521:Stroke / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
D018696:Neuroprotective Agents